<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04775147</url>
  </required_header>
  <id_info>
    <org_study_id>CRISIS I</org_study_id>
    <nct_id>NCT04775147</nct_id>
  </id_info>
  <brief_title>Intensive Control of Blood Pressure in Acute Ischemic Stroke After Endovascular Therapy on Clinical Outcome (CRISIS I)</brief_title>
  <official_title>Intensive Control of Blood Pressure in Acute Ischemic Stroke After Endovascular Therapy on Clinical Outcome:A Prospective Multicenter Randomized Controlled Trial (CRISIS I)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing First Hospital, Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing First Hospital, Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CRISIS I is a prospective, multicenter, randomized controlled trial, to asses the impact of&#xD;
      intensive blood pressure control on clinical outcome of acute ischemic stroke patients with&#xD;
      successful recanalization after endovascular therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CRISIS I aims to determine the effectiveness of more intensive BP lowering target (&lt;120 mmHg)&#xD;
      compared to standard BP management target (&lt;140mmHg) on functional outcome in patients with&#xD;
      successful recanalization post-MT for AIS due to anterior circulation large vessel occlusion&#xD;
      (LVO).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 3, 2020</start_date>
  <completion_date type="Anticipated">July 3, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 3, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Open intervention; outcome assessments undertaken by trained research staff who are kept blind to treatment allocation</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Level of disability</measure>
    <time_frame>90 days (3months)</time_frame>
    <description>a shift (improvement) in scores (0-6) on the modified Rankin scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intracerebral hemorrhage</measure>
    <time_frame>90 day</time_frame>
    <description>Any or symptomatic ICH (sICH) after endovascular therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death or neurological severity</measure>
    <time_frame>7 days</time_frame>
    <description>Death or dependency measured by National Institutes of Health stroke scale (NIHSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BP lowering target (&lt;120 mmHg)</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Achieving SBP level of &lt;120mmHg within 1 hour after successful recanalization, and maintaining this level at least 72 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Maintaining SBP level of &lt;140mmHg within 1 hour after successful recanalization, and maintaining this level at least 72 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intensive BP lowering</intervention_name>
    <description>The aim is to achieve a systolic BP level of &lt;120mmHg within 1hour after successful recanalization and to maintain this BP level for the next 72 hours (or until hospital discharge or death of this should occur earlier)</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Diagnosis of AIS with anterior circulation LVO confirmed by brain imaging&#xD;
&#xD;
          -  To receive MT &lt;24 hours after AIS onset according to local guidelines&#xD;
&#xD;
          -  Successful recanalization (TICI score ≥2b) after MT&#xD;
&#xD;
          -  Sustained systolic BP ≥140 mmHg (defined as 2 successive readings &lt;10 mins) within 60&#xD;
             minutes after recanalization&#xD;
&#xD;
          -  Provide written informed consent (or approved surrogate)&#xD;
&#xD;
          -  Perform CTA or MRI before endovascular therapy&#xD;
&#xD;
          -  Signed an approved informed consents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant pre-stroke disability (mRS scores 2-5)&#xD;
&#xD;
          -  Definite indication/contraindication to different intensities of BP lowering treatment&#xD;
&#xD;
          -  Specific contraindications to any of the BP agents to be used (eg, patients who are&#xD;
             hypersensitive (allergic) to any of the ingredients)&#xD;
&#xD;
          -  Unlikely to potentially benefit from therapy (e.g. advanced dementia) or very high&#xD;
             likelihood of death within 24 hours post-MT, judged by responsible treating clinician&#xD;
&#xD;
          -  Other medical illness that interferes with outcome assessments and follow-up&#xD;
             (e.g.advance cancer and renal failure); Women who are lactating&#xD;
&#xD;
          -  Other conditions inappropriate for inclusion judged by investigators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nanjing First Hospital, Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junshan Zhou, M.D.</last_name>
      <phone>+86025-87726218</phone>
      <email>zhjsh333@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Qiwen Deng, M.D.</last_name>
      <phone>+86025-87726218</phone>
      <email>qiw_deng@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mechanical thrombectomy</keyword>
  <keyword>Blood pressure management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

